In the orthotopic KPC1 model where Slc4a4 targeting per se already displayed a strong reduction in tumor growth, we could observe a trend in tumor growth reduction by adding the treatment with anti-PD-1 and anti-CTLA-4 together (Fig. 8g). Here, SLC4A4 is linked to neoplasm.